CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-α agonists secretion in graves' and normal thyrocytes

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Frascerra, Silvia ^a   Pupilli, Cinzia ^b   Mancusi, Caterina ^a   Metelli, Maria Rita ^c   Orlando, Claudio ^b   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFIBRATE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN SECRETION; THYROID CELL;

EID: 78650041621     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0923     Document Type: Article

References (40)

1. Kota BP, Huang TH, Roufogalis BD 2005 An overview on biological mechanisms of PPARs. Pharmacol Res 51:85-94
2. Berger JP, Akiyama TE, Meinke PT 2005 PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244-251 (Pubitemid 40603072)
3. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W 2006 International Union of Pharmacology. LXI. Peroxisome proliferator-activator receptors. Pharmacol Rev 58:726-741
4. Kielian T, Drew PD 2003 Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation. J Neurosci Res 71:315-325
5. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK 2004 Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease. J Immunol 172:5790-5798
6. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muià C, Centorrino T, Caputi AP 2004 Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors α (PPAR-α) in the development of inflammatory bowel disease in mice. Lab Invest 84:1643-1654
7. Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, Lytle C, Straus DS 2007 Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10 deficient mice. Gastroenterology 133:108-123 (Pubitemid 47031123)
8. Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, Frossard N, Pons F 2005 PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res 6:91
9. Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, Thiemermann C 2003 Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor γ. Arthritis Rheum 48:3544-3556
10. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N 2005 Inhibition of NF-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23:323-330
11. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D 2005 The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoyl ethanolamide. Mol Pharmacol 67:15-19 (Pubitemid 40069962)
12. Oliveira AC, Bertollo CM, Rocha LT, Nascimento Jr EB, Costa KA, Coelho MM 2007 Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPARα, and pioglitazone, an agonist of PPARγ. Eur J Pharmacol 561:194-201
13. Ivashchenko CY, Duan SZ, Usher MG, Mortensen RM 2007 PPAR-γ knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone caerulein-induced acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 293:G319-G326
14. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T 2004 Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate. J Biol Chem 279:16154-16160
15. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, Kelly CJ 2002 Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 168:2795-2802
16. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B 1999 Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274:32048-32054
17. Delerive P, Gervois P, Fruchart JC, Staels B 2000 Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-activators. J Biol Chem 275:36703-36707
18. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 161:195-206
19. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499
20. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M 2005 Increase of interferon-γ inducible α chemokine CXCL10 but not β chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152:171-177
21. García-López MA, Sancho D, Sánchez-Madrid F, Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 86:5008-5016
22. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 59:207-213
23. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P 2006 Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93:1226-1231
24. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E 2007 Iodine-131 given for therapeutic purposes modulates differently interferon-γ-inducible α-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 92:1485-1490
25. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E 2006 Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J Clin Endocrinol Metab 91:614-620
26. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E 2009 Monokine induced by interferon γ (IFNγ) (CXCL9) and IFNγ inducible T-cell α-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J Clin Endocrinol Metab 94:1803-1809
27. Kasai K, Banba N, Hishinuma A, Matsumura M, Kakishita H, Matsumura M, Motohashi S, Sato N, Hattori Y 2000 15-Deoxy-Delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes. Am J Physiol Cell Physiol 279:C1859-C1869
28. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408
29. Xu J, Chavis JA, Racke MK, Drew PD 2006 Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 176:95-105
30. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM1998 p48/STAT-1 α-containing complexes play a predominant role in induction of IFN-γ-inducible protein, 10kDA (IP-10) by IFN-γ alone or in synergy with TNF-γ. J Immunol 161:4736-4744
31. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK 1998 The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82
32. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK 2005 A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437:759-763
33. Leung TH, Hoffmann A, Baltimore D 2004 One nucleotide in a κB site can determine cofactor specificity for NF-κB dimers. Cell 118:453-464
34. Kwon JH, Keates S, Simeonidis S, Grall F, Libermann TA, Keates AC 2003 ESE-1, an enterocyte-specific Ets transcription factor, regulates MIP-3α gene expression in Caco-2 human colonic epithelial cells. J Biol Chem 278:875-884
35. Wu GD, Lai EJ, Huang N, Wen X 1997 Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. The role of Oct-1 as a transcriptional repressor. J Biol Chem 272:2396-2403
36. Wood LD, Richmond A 1995 Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO α gene requires both NF-κB and novel constitutive factors. J Biol Chem 270:30619-30626
37. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD 2000 Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164:6503-6508
38. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ 2005 Intestinal antiinflammatory effects of thiazolidinedione peroxisome proliferator-activated receptor-γ ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 11:244-252
39. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M, Galli A, Serio M, Luconi M 2008 A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-α and interferon-γ inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol 28:718-724
40. Nie M, Corbett L, Knox AJ, Pang L 2005 Differential regulation of chemokine expression by peroxisome proliferator-activated receptor γ agonists: interactions with glucocorticoids and β2-agonists. J Biol Chem 280:2550-2561